Trials / Completed
CompletedNCT00425737
Assess Efficacy, Immune Response & Safety of 2 Doses of Oral Live Attenuated HRV Vaccine in Healthy Infants
A Study to Assess the Efficacy, Immunogenicity and Safety of Two Doses of Oral Live Attenuated Human Rotavirus (HRV) Vaccine (Rotarix) in Healthy Infants.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 405 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 6 Weeks – 12 Weeks
- Healthy volunteers
- Accepted
Summary
To assess the efficacy, immune response and safety of the oral live attenuated HRV vaccine (Rotarix) in healthy infants approximately 2 months of age and previously uninfected with human rotavirus
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Rotarix |
Timeline
- Start date
- 2000-08-01
- Primary completion
- 2001-07-01
- Completion
- 2001-07-01
- First posted
- 2007-01-23
- Last updated
- 2016-09-16
Source: ClinicalTrials.gov record NCT00425737. Inclusion in this directory is not an endorsement.